Showing results (871-880 of 928) with videos related to

Sort By:
Pageof 93
The Lancet. Diabetes & Endocrinology|April 18, 2021
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trialsGeorge J Kahaly, Raymond S Douglas, Robert J Holt, et al.
The Lancet. Diabetes & Endocrinology|January 24, 2026
Effect of surgical versus conservative management on cardiovascular outcomes in patients with bilateral adrenal tumours and cortisol excess: an international, retrospective cohort studyElisabeth Nowak, Charlotte L Viëtor, Richard A Feelders, et al.
The Lancet. Diabetes & Endocrinology|February 9, 2023
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 studyJuan Frias, Jenny Chien, Qianyi Zhang, et al.
The Lancet. Diabetes & Endocrinology|February 23, 2023
Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control studyLise Folon, Morgane Baron, Bénédicte Toussaint, et al.
The Lancet. Diabetes & Endocrinology|February 4, 2023
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trialLori M Laffel, Thomas Danne, Georgeanna J Klingensmith, et al.
The Lancet. Diabetes & Endocrinology|July 25, 2020
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trialsDennis M Black, Douglas C Bauer, Eric Vittinghoff, et al.
The Lancet. Diabetes & Endocrinology|July 25, 2020
Endocrine-disrupting chemicals: economic, regulatory, and policy implicationsChristopher D Kassotis, Laura N Vandenberg, Barbara A Demeneix, et al.
The Lancet. Diabetes & Endocrinology|May 21, 2014
Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment
The Lancet. Diabetes & Endocrinology|May 17, 2014
Adrenal vein sampling in primary aldosteronism: towards a standardised protocolSilvia Monticone, Andrea Viola, Denis Rossato, et al.
The Lancet. Diabetes & Endocrinology|June 6, 2014
Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targetsChristine Spitzweg, Keith C Bible, Lorenz C Hofbauer, et al.
Pageof 93